Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 216

1.

Positive regulatory domain I-binding factor 1 mediates repression of the MHC class II transactivator (CIITA) type IV promoter.

Chen H, Gilbert CA, Hudson JA, Bolick SC, Wright KL, Piskurich JF.

Mol Immunol. 2007 Feb;44(6):1461-70. Epub 2006 Jun 12.

2.

MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma.

Zhao M, Flynt FL, Hong M, Chen H, Gilbert CA, Briley NT, Bolick SC, Wright KL, Piskurich JF.

Mol Immunol. 2007 Apr;44(11):2923-32. Epub 2007 Feb 14.

3.
4.

Expression of the MHC class II transactivator (CIITA) type IV promoter in B lymphocytes and regulation by IFN-gamma.

Piskurich JF, Gilbert CA, Ashley BD, Zhao M, Chen H, Wu J, Bolick SC, Wright KL.

Mol Immunol. 2006 Feb;43(6):519-28. Epub 2005 Jun 13.

5.

Positive regulatory domain I binding factor 1 silences class II transactivator expression in multiple myeloma cells.

Ghosh N, Gyory I, Wright G, Wood J, Wright KL.

J Biol Chem. 2001 May 4;276(18):15264-8. Epub 2001 Jan 30.

7.
8.

IFN-gamma regulation of the type IV class II transactivator promoter in astrocytes.

Dong Y, Rohn WM, Benveniste EN.

J Immunol. 1999 Apr 15;162(8):4731-9.

9.

Activated human T cells accomplish MHC class II expression through T cell-specific occupation of class II transactivator promoter III.

Holling TM, van der Stoep N, Quinten E, van den Elsen PJ.

J Immunol. 2002 Jan 15;168(2):763-70.

10.
11.

The Smad3 protein is involved in TGF-beta inhibition of class II transactivator and class II MHC expression.

Dong Y, Tang L, Letterio JJ, Benveniste EN.

J Immunol. 2001 Jul 1;167(1):311-9.

12.

Thyrotropin-mediated repression of class II trans-activator expression in thyroid cells: involvement of STAT3 and suppressor of cytokine signaling.

Kim H, Suh JM, Hwang ES, Kim DW, Chung HK, Song JH, Hwang JH, Park KC, Ro HK, Jo EK, Chang JS, Lee TH, Lee MS, Kohn LD, Shong M.

J Immunol. 2003 Jul 15;171(2):616-27.

14.

Differential usage of class II transactivator promoters PI and PIV during inflammation and injury in kidney.

Takeuchi O, Sims TN, Takei Y, Ramassar V, Famulski KS, Halloran PF.

J Am Soc Nephrol. 2003 Nov;14(11):2823-32.

15.

Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines.

Goodwin BL, Xi H, Tejiram R, Eason DD, Ghosh N, Wright KL, Nagarajan U, Boss JM, Blanck G.

Cell Growth Differ. 2001 Jun;12(6):327-35.

17.
18.

BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells.

Piskurich JF, Lin KI, Lin Y, Wang Y, Ting JP, Calame K.

Nat Immunol. 2000 Dec;1(6):526-32.

PMID:
11101876

Supplemental Content

Support Center